No Data
No Data
Scotiabank Maintains Legend Biotech(LEGN.US) With Buy Rating, Raises Target Price to $70
Scotiabank analyst George Farmer maintains $Legend Biotech(LEGN.US)$ with a buy rating, and adjusts the target price from $65 to $70.According to TipRanks data, the analyst has a success rate of 60.2%
Scotiabank Maintains Sector Outperform on Legend Biotech, Raises Price Target to $70
Scotiabank analyst George Farmer maintains Legend Biotech with a Sector Outperform and raises the price target from $65 to $70.
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining around 150 points on Thursday.Shares of Cintas Corporation (NASDAQ:CTAS) rose during Thursday's session after the company reported better-
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $70 to $94
On Jul 18, major Wall Street analysts update their ratings for $Legend Biotech(LEGN.US)$, with price targets ranging from $70 to $94.Barclays analyst Gena Wang maintains with a buy rating, and
Scotiabank Sticks to Their Buy Rating for Legend Biotech (LEGN)
Buy Rating on Legend Biotech: Strong Carvykti Sales and High Market Potential Signal Upside